Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 3, 2021
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...
-
Feb 12, 2021
CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...
-
Feb 2, 2021
Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieriand Gilbert Achermann will not stand for re-election St. Gallen, Switzerland, 02 February 2021
-
Jan 31, 2021
24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...
-
Jan 25, 2021• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.
NEW YORK – (January 25, 2021) – Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community...
-
Dec 21, 2020
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from...
-
Dec 14, 2020
This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...
-
Dec 14, 2020
Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...
-
Dec 11, 2020
11 Dec 2020 The University of Queensland (UQ) and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and...
-
Dec 9, 2020First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...